Last10K.com

Esperion Therapeutics, Inc. (ESPR) SEC Filing 8-K Material Event for the period ending Wednesday, June 1, 2022

Esperion Therapeutics, Inc.

HISTORY TOOLS
CIK: 909037 Ticker: ESPR

View differences made from one to another to evaluate Esperion Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Esperion Therapeutics, Inc..

Continue

Assess how Esperion Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Esperion Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Cover Page

Material Contracts, Statements, Certifications & more

Esperion Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: ESPR
CIK: 1434868
Form Type: 8-K Corporate News
Accession Number: 0001628280-22-015897
Submitted to the SEC: Wed Jun 01 2022 4:10:31 PM EST
Accepted by the SEC: Wed Jun 01 2022
Period: Wednesday, June 1, 2022
Industry: Pharmaceutical Preparations
Events:
  1. Event for Officers
  2. Financial Exhibit
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/espr/0001628280-22-015897.htm